Skip to main content

CORRECTION article

Front. Neurosci. , 28 February 2020

Sec. Neuropharmacology

Volume 14 - 2020 | https://doi.org/10.3389/fnins.2020.00163

Corrigendum: Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond

This article is a correction to:

  1. Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond

    1. Read original article
\nXiaoli Wang,&#x;Xiaoli Wang1,2†Guoyi Li&#x;Guoyi Li1†Jingkang GuoJingkang Guo2Zhiping ZhangZhiping Zhang2Shuzhang ZhangShuzhang Zhang2Yudan ZhuYudan Zhu1Jiwei ChengJiwei Cheng1Lu YuLu Yu1Yonghua Ji, Yonghua Ji2,3*Jie Tao, Jie Tao1,4*
  • 1Department of Neurology and Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2Institute of Biomembrane and Biopharmaceutics, Shanghai University, Shanghai, China
  • 3Xinhua Translational Institute for Cancer Pain, Shanghai, China
  • 4Putuo Clinical Medical School, Anhui Medical University, Shanghai, China

A Corrigendum on
Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond

by Wang, X., Li, G., Guo, J., Zhang, Z., Zhang, S., Zhu, Y., et al. (2020). Front. Neurosci. 13:1393. doi: 10.3389/fnins.2019.01393

In the original article, we neglected to include the funder Youth Talent Promotion Project of China Association of Chinese Medicine, grant no. 2019-QNRC2-C10 to Jie Tao. In addition, the order of the affiliations was incorrect. Affiliations 1 and 2 have been switched and the change is reflected above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Kv1.3, ShK, neuroinflammatory disease, multiple sclerosis, stroke, epilepsy, Alzheimer's disease, Parkinson's disease

Citation: Wang X, Li G, Guo J, Zhang Z, Zhang S, Zhu Y, Cheng J, Yu L, Ji Y and Tao J (2020) Corrigendum: Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond. Front. Neurosci. 14:163. doi: 10.3389/fnins.2020.00163

Received: 29 January 2020; Accepted: 12 February 2020;
Published: 28 February 2020.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2020 Wang, Li, Guo, Zhang, Zhang, Zhu, Cheng, Yu, Ji and Tao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yonghua Ji, eWhqaUBzdGFmZi5zaHUuZWR1LmNu; Jie Tao, amlldGFvX3B1dHVvQGZveG1haWwuY29t

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more